[{"id":"2be3bc28-b41c-488c-9d96-7369def4b45c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05549557","created_at":"2022-09-22T15:56:27.450Z","updated_at":"2024-07-02T16:36:03.609Z","phase":"Phase 1","brief_title":"IMM40H Phase I Dose Escalation and Expansion","source_id_and_acronym":"NCT05549557","lead_sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMM40H"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-09-22"}]